September 3, 2008 - IntraOp will discuss at ASTRO 2008 the recent results of the study which found that a single dose of Intraoperative electron radiotherapy (IOERT) delivered in a single day may be equivalent to six weeks of standard, daily radiation for breast cancer patients.

According to the study, led by by Umberto Veronesi, M.D., director of the European Institute of Oncology in Milan, Italy, a breast surgeon who has pioneered the use of IOERT for this purpose, a single dose of intraoperative electron-beam radiation can be equal to the traditional six-week course for women with breast cancer. The only FDA-approved device available in North America that is capable of delivering the IOERT treatment extolled by Dr. Veronesi in an unshielded operating room is IntraOp’s Mobetron. The Mobetron is a fully portable, self-shielded linear accelerator that can be used in an existing operating room.

Dr. Veronesi presented the results from the first findings of his randomized trial at the recent ISIORT conference in Madrid, Spain, in June 2008. Patients were divided into two groups that received one of two types of treatment: breast conserving surgery and a single dose of IOERT; and breast conserving surgery and traditional six weeks of post-operative radiation therapy. Dr. Veronesi’s study reported that, to date, women who received a single dose of IOERT had identical control, survival and cosmetic results as those who underwent the standard six-week radiation regimen.

From these results, Dr. Veronesi concluded that a single dose of IOERT may be equivalent in outcome to six weeks of post-operative radiation therapy.

For more information: www.intraopmedical.com


Related Content

News | Proton Therapy

June 14, 2024 — Atlantic Health System, an integrated health care system setting standards for quality health care in ...

Time June 14, 2024
arrow
News | Oncology Information Management Systems (OIMS)

May 21, 2024 — RaySearch Laboratories AB announced that the oncology information system RayCare* 2024A has been ...

Time May 21, 2024
arrow
News | Artificial Intelligence

May 14, 2024 — Elekta announced the launch of its latest linear accelerator (linac), Evo*, a CT-Linac with new high ...

Time May 14, 2024
arrow
News | Proton Therapy

January 26, 2024 — P-Cure continues its quest to successfully usher in a new era of clinical treatment with proton ...

Time January 26, 2024
arrow
News | Linear Accelerators

October 25, 2023 — A new order for several Elekta Harmony linear accelerators (linacs) in Ukraine will complement the ...

Time October 25, 2023
arrow
News | Radiation Therapy

October 5, 2023 — A new study, led by radiation oncology physicists at Miami Cancer Institute, part of Baptist Health ...

Time October 05, 2023
arrow
News | Oncology Information Management Systems (OIMS)

May 24, 2023 — RaySearch Laboratories AB announced that the oncology information system RayCare* (* subject to ...

Time May 24, 2023
arrow
News | Proton Therapy

April 3, 2023 — P-Cure announced clearance of its Adaptive Proton Therapy Solution by the FDA for sales in the USA. P ...

Time April 03, 2023
arrow
News | Radiation Therapy

February 28, 2023 — Elekta announced that Comprehensive Motion Management (CMM) with True Tracking and automatic gating ...

Time February 28, 2023
arrow
News | Radiation Therapy

February 6, 2023 — Varian, a Siemens Healthineers company, announced that it has received 510(k) clearance from the U.S ...

Time February 06, 2023
arrow
Subscribe Now